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ABSTRACT
Protein kinase CK2 promotes cell survival and the
activity of this kinase is elevated in several cancers
including chronic myeloid leukaemia. We have
shown previously that phosphorylation of the
Proline-Rich Homeodomain protein (PRH/Hhex) by
CK2 inhibits the DNA-binding activity of this tran-
scription factor. Furthermore, PRH represses the
transcription of multiple genes encoding compo-
nents of the VEGF-signalling pathway and thereby
influences cell survival. Here we show that the in-
hibitory effects of PRH on cell proliferation are
abrogated by CK2 and that CK2 inhibits the
binding of PRH at the Vegfr-1 promoter.
Phosphorylation of PRH by CK2 also decreases
the nuclear association of PRH and induces its
cleavage by the proteasome. Moreover, cleavage
of phosphorylated PRH produces a stable truncated
cleavage product which we have termed
PRH"C (Hhex"C). PRH"C acts as a transdominant
negative regulator of full-length PRH by sequester-
ing TLE proteins that function as PRH co-
repressors. We show that this novel regulatory
mechanism results in the alleviation of PRH-
mediated repression of Vegfr-1. We suggest that
the re-establishment of PRH function through inhib-
ition of CK2 could be of value in treatment of
myeloid leukaemias, as well as other tumour types
in which PRH is inactivated by phosphorylation.
INTRODUCTION
Protein kinase CK2 (Casein Kinase II) is a serine/threo-
nine protein kinase that functions to promote cell survival
by regulating the activity of proteins involved in many
processes in the cell including transcription, cell signalling,
cell-cycle control and DNA repair (1–3). The active CK2
enzyme is a tetramer consisting of two catalytic a subunits
and two regulatory b subunits that modulate kinase
activity, substrate speciﬁcity and sub-cellular localization
(2). CK2 activity is elevated in several cancer types (4)
including Acute Myeloid Leukaemia (AML) and
Chronic Myeloid Leukaemia (CML) (5,6). Phosphory-
lation by CK2 alters the activity and/or stability of the
tumour suppressor proteins p53, PML and PTEN,
changing their afﬁnity for their respective targets and/or
altering their degradation by the proteasome, ultimately
leading to increased cell survival (1). CK2 activity also
inhibits the degradation of several oncoproteins and
other pro-survival proteins again leading to enhanced
cell survival. Additionally CK2 has an anti-apoptotic
role and inactivates a number of proteins involved in
promoting apoptosis (1–3).
The Proline-Rich Homeodomain (PRH/Hhex) protein
regulates many processes in embryonic development and
in the adult [reviewed (7)]. In the haematopoietic system
PRH is expressed in all myeloid lineages where it functions
as a negative regulator of cell proliferation (8–10). PRH
interacts with eIF4E and inhibits the mRNA transport of
proliferation control mRNAs such as the cyclin D1
mRNA (8,11). PRH also interacts with the PML protein
although the importance of this interaction in the control
of cell proliferation is not known (11). Loss of PRH
function in myeloid cells contributes to the development
of AML subtypes and blast crisis CML (12,13). Outside
the haematopoietic system, down-regulation and
mislocalization of PRH is associated with thyroid cancer
and breast cancer (14,15).
PRH is an oligomeric transcription factor that binds to
tandem arrays of PRH-binding sites inducing signiﬁcant
DNA condensation (16,17). PRH can activate or repress
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the transcription of its target genes. One mechanism that
PRH uses to repress transcription involves the recruitment
of members of the TLE/Groucho family of co-repressor
proteins (18). TLE co-repressors are recruited to pro-
moters through interaction with a DNA-binding tran-
scription factor, bind directly to non-acetylated histones
and recruit histone deacetylases to bring about transcrip-
tional repression (19). An Eh1 motif present in the
N-terminal repression domain of PRH mediates the
binding of PRH to TLE proteins and this motif is
required for co-repression (18). We have shown that
PRH regulates haematopoietic and breast cell survival
through the direct transcriptional repression of multiple
genes encoding components of the VEGF-signalling
pathway (VSP) including Vegf, Vegfr-1, Vegfr-2 and
neuropillin-1 (10,20). VEGF signalling is required for
normal angiogenesis and haematopoiesis and elevated
VSP activity is often associated with leukaemias and
solid tumours, suggesting that deregulation of this
pathway commonly occurs in tumourigenesis (21).
Our recent work showed that phosphorylation of PRH
by CK2 inhibits the DNA-binding activity of this protein
(20). Here we show that CK2 abrogates the inhibitory
effect of PRH on the proliferation of haematopoietic
cells and we reveal multiple additional mechanisms
through which the phosphorylation of PRH leads to the
inhibition of PRH activity and the up-regulation of
VEGF-signalling genes.
MATERIALS AND METHODS
Expression plasmids
pMUG1-Myc-PRH expresses human PRH tagged with the
Myc9E10 epitope (18). pMUG1-Myc-PRH S163E,S177E
was described previously (20). pMUG1-Myc-PRH
S163C,S177C, pMUG1-Myc-PRH S163E,S177E 211
and pMUG1-Myc-PRH S163E,S177E 211 F32E were
created using a Quikchange mutagenesis kit according to
the manufacturer’s instructions. pRc/CMV-CK2a-HA,
pRc/CMV-HACK2b and pRc/CMV-CK2a-K68M-HA
express HA-tagged CK subunits and a kinase-dead
CK2a mutant respectively and were a gift from Professor
D. Litchﬁeld (University ofWestern Ontario). The plasmid
expressing FLAG tagged TLE1 was a gift from Professor
S. Stifani (McGill University) and has been described pre-
viously (18).
Cell culture, transient transfections and knockdown
experiments
K562 cells were obtained from Professor C. Bunce
(University of Birmingham) and originally purchased
from ATCC. K562 cells were checked for glycophorinA
expression using PCR and antibodies. Cell culture and
transient transfections were performed as described previ-
ously using equal amounts of total DNA in each case
(18,22). PRH knockdown (PRH KD) cells were
produced as described previously (10).
Co-immunoprecipitation assays and western blotting
Co-immunoprecipitation assays were performed exactly as
described previously (18,22). An amount of 20 mg of cell
extract was used in western blotting experiments with
PRH and phosphorylated PRH (pPRH) antibodies (16).
Inhibitor experiments
Control or PRH shRNA KD cells were incubated with
80 mM DMAT (2-dimethylamino-4,5,6,7-tetrabromo-1H-
benzimidazole, Calbiochem) for 24 h. Protein stability
experiments were performed with K562 cells treated with
40 mM Anisomycin (Sigma) for 4, 8 or 24 h. Proteasome
activity was inhibited with 10 mMMG132 (Sigma) for 4, 8
or 24 h.
In situ cell fractionation and biochemical fractionation
In situ cell fractionation was performed as described pre-
viously (23). Brieﬂy, poly-L-transfected K562 cells were
plated onto lysine coated microscope coverslips.
Cytoplasmic and loosely held nuclear proteins were
removed as required using CSK buffer (10mM PIPES,
300mM Sucrose, 100mM NaCl, 3mM MgCl2, 1mM
EGTA). Untreated cells and extracted cells were ﬁxed in
4% parafomaldehyde for 30min, rinsed with PBS and
incubated with PBS+3% BSA for 40min. The cells
were then incubated with either rabbit anti-HA polyclonal
antibody (Sigma), rabbit anti-Myc9E10 antibody (Cell
Signalling), rabbit Lamin B antibody (Santa Cruz
Biotechnology) or a mouse Tubulin antibody (Sigma)
and the appropriate secondary antibodies (Stratec).
Coverslips were mounted with DAPI (40,6-diamidino-
2-phenylindole)-containing mounting medium (Vec-
tashield) and viewed on a Leica DM IRBE confocal
microscope. Imaging was performed using Leica
Confocal Software Version 2.00.
Biochemical fractionation for western analysis was per-
formed as described previously (22). Brieﬂy, whole-cell
extracts were prepared using TES buffer (1% SDS,
2mM EDTA, 20mM Tris–HCl pH 7.4), cytoplasmic
and loosely held nuclear proteins (PN fraction) were
prepared using CSK buffer (10mM PIPES, 300mM
Sucrose, 100mM NaCl, 3mM MgCl2, 1mM EGTA)
and nuclear extracts were prepared using CSK buf-
fer+0.5% (V/V) Triton X-100.
Cell proliferation and apoptosis assays
Viable cells were counted 48 h post-transfection using
trypan blue exclusion. Apoptotic cells were detected 24 h
post-transfection in the absence and presence of
100 mM Z-VAD-FMK [N-Benzyloxycarbonyl-Val-Ala-
Asp(OMe)-ﬂuoromethylketone] (Abcam) using Annexin
V staining (10). Results were analysed for signiﬁcance
using the unpaired students t-test. After 24 h
Annexin V FACs staining was performed as previously
described.
Quantitative ChIP
For ChIP K562 cells (107 cells per ChIP) were transiently
transfected with 5 mg of pMUG1-Myc-PRH expression
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vector per chromatin preparation. ChIP was carried out as
described in (17) with the following modiﬁcations. After
cross linking cells were re-suspended in lysis buffer [50mM
Tris–Cl pH 8, 10mM EDTA, 1% SDS, 1mM PMSF,
protease inhibitor cocktail tablet (Roche)] and divided
into 5 106 fractions for sonication. Lysates were sonicated
in a Biorupter (Diagenode) for 10min at 4C on medium
power. For assessment of sonication efﬁciency, 10%of each
sonicated chromatin lysate was incubated with proteinase
Kat 68C for 2 h.DNAwas then puriﬁed by phenol/chloro-
form extraction and ethanol precipitation and assessed for
fragment size distribution by electrophoresis on a 1.5%
agarose gel. For ChIP, 25 mg of chromatin lysate was
incubated with Protein A magnetic beads (Dynabeads
Invitrogen) and Myc antibody (9E10 NE Biolabs) or IgG
antibody (Invitrogen) for 16 h at 4C. Beads were collected
with amagnet and thenwashed twice inwashbuffer (10mM
Tris–Cl pH 7.5, 1mM EDTA, 0.5mM EGTA, 1% Triton
X-100, 0.1%SDS, 0.1%Na–deoxycholate, 140mMNaCl),
twice in wash buffer with 500mM NaCl, twice in wash
buffer with 0.5% NP40 and twice in TE. DNA was eluted
using elution buffer (20mM Tris–Cl pH 7.5, 5mM EDTA,
50mM NaCl, with 1% SDS). After treatment with
Proteinase K for 2 h at 68C the DNA was puriﬁed by
phenol/chloroform extraction and ethanol precipitation.
Quantitative PCR (qPCR) with the primers shown
below was used to determine the relative amount of
binding across the Vegfr-1 promoter. qPCR speciﬁc
controls: a calibration line, melting curve analysis and
the no-template control were performed for each primer
pair. Equal concentrations of input and immunopre-
cipitated DNA were used for qPCR. To ﬁnd the
normalized signal ratio, the relative level of a genomic
Vegfr-1 sequence was compared to the relative level of a
genomic Glyceraldehyde-3-phosphate dehydrogenase
(Gapdh) sequence, as the Gapdh promoter is known not
to be regulated by PRH. From this normalized signal ratio
an enrichment ratio was calculated by comparing the
normalized signal ratio for the immunoprecipitated
DNA to the normalized signal ratio for the input DNA.
IgG immunoprecipitated DNA was compared to input
DNA in a similar fashion.
qPCR reactions were performed using a Rotogene
RG-3000 (Corbett) with SYBR green master
mix (Bioline). Reactions were incubated at 95C for
10min before 40 cycles of 95C for 10 s, 60C for 20 s,
72C for 5 s.
Vegfr-1 primers pairs:
P5 R1 7500 forward 50-CTTCTCCGTGCTACTTCTTT
CTGC-30 reverse 50-GGCCAGAGCTTTGGTTTCACT
GAT-30
P4 LM V forward 50-TAGCTGAGACTACAGGCA
CAC-30 reverse 50-CTCTGGTTAGCAGTTCAGGGA-30
P3 LM III forward 50-ACGCTGCTCTTCCCACCT
GAA-30 reverse 50-ACGCTCCAGAAATTCCATCCAG
CA-30
P2 R1 c3 forward 50-CCTTGGTGTGCAGCCCAGAAA
TG-30 reverse 50-TAGTCCTATTGGAACCCGTCAGA
G-30
P1 R1 c2 forward 50-GATTACCCGGGGAAGTGGTT
GTCT-30 reverse 50-CCCCAGCCGCGCCTCACCT
GT-30
P+1 R1+1700 forward 50-TCTTTCTCAGTGGGAAGA
CTAACTAGACC-30 reverse 50-GTTATGTTAGCACCT
TTCCCAACCTACAG-30
GAPDH genomic primer pair:
Forward 50-ACCCCTTTCACCATTAGGGACCTT-30
reverse 50-AGCCTGCCTGGTGATAATCTTTGC-30
Quantitative reverse transcriptase-mediated PCR
RNA was produced following standard protocols and
analysed as described previously (10). The qPCR was per-
formed in triplicate using the primers listed below, and the
data were analysed using Rotorgene 6 software (Corbett
Research; Rotorgene RG-3000). Gapdh mRNA was used
as an internal control.
qRT–PCR primer pairs:
Vegfr-1 forward 50-TGGCCATCACTAAGGAGCACTC
C-30 reverse 50-GGAACTGCTGATGGCCACTGTG-30
Vegf forward 50-ATCAGCGCAGCTACTGCCATCC-30
reverse 50-TCTCCTATGTGCTGGCCTTGGTG-30
GAPDH forward 50-TGATGACATCAAGAAGGTGGT
GAAG-30 reverse 50-TCCTTGGAGGCCATGTGGGCC
AT-30
RESULTS
CK2 activity alleviates the repression of VSP genes
by PRH
K562 cells are a CML cell line that express VEGF,
VEGFR-1 and PRH. Chromatin immunoprecipitation
(ChIP) assays have shown that PRH can bind directly to
the Vegf and Vegfr-1 promoters in these cells (10).
Knockdown of PRH in K562 cells results in the de-
repression of Vegf and Vegfr-1 and, conversely, a 2- to
3-fold over-expression of PRH represses transcription of
these genes (10). Although phosphorylation of PRH by
CK2 can inhibit the binding of PRH to DNA, the
degree to which this inhibits the repression of Vegf and
Vegfr-1 transcription by PRH is not known. To determine
whether increased CK2 activity alleviates the repression of
these genes by PRH we over-expressed CK2 and PRH in
K562 cells. We transiently transfected K562 cells with
either an empty vector control (EVC), PRH expression
vector alone, or with expression vectors for PRH and
CK2. This results in a modest 2- to 3-fold over-expression
of PRH (10). After 48 h Vegfr-1 mRNA levels were
measured using quantitative PCR (qPCR). Over-
expression of PRH causes a decrease in Vegfr-1 mRNA
levels to 30% of the unrepressed value (Figure 1A).
However, in the presence of co-expressed CK2a and
CK2b, Vegfr-1 mRNA levels are only weakly repressed
(Figure 1A). CK2b alone fails to block repression by
PRH as does CK2b and a kinase inactive K2a mutant
(CK2aK68M). Similar results were obtained using
qPCR to measure Vegf mRNA levels (Figure 1B).
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Over-expression of CK2 has no effect on PRH protein
levels (Figure 6C). We conclude that repression of the
Vegfr-1 and Vegf genes by over-expressed PRH is
reversed by over-expression of CK2. Over-expression of
CK2 subunits in the absence of PRH has no effect of the
expression of either Vegfr-1 or Vegf (Supplementary
Figure S1). This suggests that endogenous PRH is max-
imally phosphorylated, either because it is tightly bound
to DNA, or because it is present in other complexes that
block phosphorylation.
Incubation of K562 cells with the CK2 inhibitor
DMAT signiﬁcantly decreases the amount of pPRH
(20). To conﬁrm that phosphorylation by CK2 antagon-
izes the repression of Vegf and Vegfr-1 by PRH we made
use of PRH KD cells. Control cells and PRH KD cells
(Figure 1C) were incubated with DMAT or left untreated
and after 24 h Vegfr-1 and Vegf mRNA levels were
determined using qPCR. In the control cells Vegfr-1
mRNA levels are signiﬁcantly lower in the presence of
DMAT (Figure 1D, 1 and 2). As expected, Vegfr-1
mRNA levels are much higher in PRH KD cells than
in the control cells (Figure 1D, 3). However, in PRH
KD cells treatment with DMAT fails to decrease
Vegfr-1 mRNA levels (3 and 4). Very similar results
were obtained using qPCR to measure Vegf mRNA
levels (Figure 1E). Thus DMAT treatment results in
increased repression of Vegfr-1 and Vegf only when
PRH is present.
A
D E
B C
Figure 1. CK2 alleviates the repression of VSP genes by PRH. (A) Vegfr-1 mRNA levels in K562 cells 48 h post-transfection with empty vector (1),
plasmid expressing Myc-PRH (5mg) (2) or plasmids expressing Myc-PRH (5 mg) and HA-CK2 subunits (3 mg each) (3–5). mRNA levels were
determined by qPCR and compared to Gapdh. Mean and standard deviation (M+SD), n= 5. ** indicates P< 0.005, ns indicates not signiﬁcant.
(B) Vegf mRNA levels in K562 cells transfected as in (A) determined as above. M+SD, n= 5. (C) PRH protein levels after transfection with
scrambled vector control (SVC)(1) or PRH shRNA (2) followed by selection using puromycin. Endogenous PRH was detected using PRH-speciﬁc
antibodies. (D) Vegfr-1 mRNA levels after PRH KD. Control and PRH KD cells were treated with 80 mM DMAT for 24 h prior to mRNA isolation.
White bars represent SVC shRNA targeted control cells and grey bars PRH shRNA targeted cells. M+SD, n= 3. **P< 0.005, ns—not signiﬁcant.
(E) Vegf mRNA levels in the cells from (D).
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CK2 antagonizes the inhibition of cell proliferation by
PRH
To determine whether the inhibitory effects of PRH on
cell proliferation are antagonized by CK2, we expressed
PRH alone, or PRH and CK2, in K562 cells and moni-
tored cell number 72 h post-transfection. Although only
35–50% of the cells are transfected under these conditions,
over-expression of PRH signiﬁcantly decreases cell
number (Figure 2A, 2). Co-expression with CK2a and
CK2b abrogates the effect of PRH on cell number (3).
In contrast, co-expression with kinase inactive CK2a
(K68M) and wild-type CK2b, or the CK2b subunit
alone does not reverse the effects of PRH over-expression
(4 and 5). Furthermore, over-expression of CK2 alone has
no effect on cell number (Supplementary Figure S2).
We have shown previously that over-expression of PRH
in K562 cells can induce apoptosis and that this can be
abrogated by over-expressing VEGF-signalling proteins
from PRH-independent reporters (10). To conﬁrm that
the pro-apoptotic activity of PRH in these cells is
blocked by CK2, the survival of the transfected cells was
measured by expressing eGFP with PRH or eGFP with
PRH and CK2 and staining the cells with propidium
iodide (for DNA) and APC-Annexin V (for apoptosis).
Flow cytometry shows that over-expression of PRH
results in >10-fold increase in the number of cells in late
apoptosis 24 h post-transfection and a more modest
increase in early apoptosis (Figure 2B, middle). In
contrast, over-expression of PRH and CK2 has very
little effect on the number of cells in apoptosis
(Figure 2B, bottom and Figure 2C). As expected,
A B
C
Figure 2. CK2 alleviates the inhibition of cell proliferation by PRH. (A) K562 cells were transfected with plasmids expressing Myc-PRH (5mg) or
Myc-PRH (5 mg) and CK2 subunits (3 mg each). Seventy-two hours post-transfection cells were counted using trypan blue exclusion. M+SD, n= 5.
* indicates P< 0.02, ns—not signiﬁcant. (B) K562 cells were transfected with 1 mg pEGFP alone (control), 1 mg pEGFP and 5 mg pMUG1-Myc-PRH
(PRH) or 1 mg pEGFP, 5 mg pMUG1-Myc-PRH and 3 mg of plasmids expressing CK2a and CK2b. The cells were dual stained with propidium iodide
(P.I.)/Annexin V (AV) (APC antibody) 24 h post-transfection and analysed by ﬂow cytometry. Cells stained with both dyes are in late apoptosis.
Cells stained for annexin V alone are in early apoptosis. The dot plot shows the percentage of live cells (PI/AV), necrotic cells (PI+), early
apoptotic cells (AV+) and late apoptotic cells (AV+/PI+) after gating for GFP+ cells. Representative data. (C) The experiment shown in (C) was
repeated three times and the graph shows the percentage of early and late apoptotic cells. * indicates P< 0.02, ns—not signiﬁcant.
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treatment with an inhibitor of apoptosis (Z-VAD-FMK)
blocks PRH-induced apoptosis (Supplementary Figure
S3A). However, the inhibition of PRH-induced apoptosis
has no effect on the down-regulation of Vegfr-1 mRNA
levels by PRH (Supplementary Figure S3). We conclude
that CK2 antagonizes the effect of PRH on apoptosis and
that this results in increased cell survival.
CK2 blocks the binding of PRH to the Vegfr-1 promoter
To examine the effects of PRH phosphorylation on VSP
gene expression and cell survival in more detail, we looked
at the effects of two mutated PRH proteins. We
introduced serine to cysteine mutations at the positions
known to be phosphorylated by CK2 to produce PRH
S163C/S177C (PRH CC). These mutations prevent phos-
phorylation by CK2 at these positions. The PRH S163E/
S177E (PRH EE) protein carries mutations of serine to
glutamate at the same positions and has been described
previously (20). The PRH EE phosphomimic is unable to
bind DNA (20). As expected, wild-type PRH represses
Vegfr-1 and CK2 over-expression counteracts this repres-
sion (Figure 3A, 2 and 3). PRH CC also represses Vegfr-1
mRNA levels but CK2 is unable to counteract this repres-
sion (Figure 3A, 4 and 5). In contrast, PRH EE is unable
to decrease Vegfr-1 expression and CK2 has no effect in
the presence of this protein (Figure 3A, 6 and 7). Western
analysis conﬁrms these proteins are expressed at equiva-
lent levels (Figure 3B).
To show that the differential effects of CK2 on PRH-
and PRH CC-mediated repression of Vegfr-1 gene expres-
sion are due to changes in DNA binding, we performed
quantitative ChIP assays. Chromatin obtained from cells
expressing PRH and the mutant PRH proteins described
above was sheared by sonication using conditions that
reproducibly produce an average fragment size of
<400 bp (Figure 3C). Figure 3D (upper panel) shows a
cartoon of the Vegfr-1 promoter and the positions of
multiple PRH-binding sites that we have identiﬁed previ-
ously (10). Quantitative ChIP shows that PRH binds to
Vegfr-1 promoter sequences extending from 5600 bp 50
and+1700 bp 30 relative to the ﬁrst exon (Figure 3D, 1).
This binding is not likely to be an artefact of
over-expression because we have shown that PRH is
only moderately over-expressed relative to endogenous
PRH in these cells (10). While the possibility that chroma-
tin fragments >400 bp result in ChIP at locations distal to
the PRH-binding sites cannot be completely excluded, the
ability of PRH to bind to degenerate sequences (10) and to
oligomerize and wrap extensive DNA sequences (17),
suggests that it is more likely that PRH binds at
multiple positions across an extended region of the
Vegfr-1 promoter. There is no enrichment for PRH in
the presence of non-speciﬁc IgG antibody. Importantly
PRH binding across the whole promoter region is lost
when PRH and CK2 are co-expressed (Figure 3D, 2). In
contrast, PRH CC binding at the Vegfr-1 promoter is not
blocked by CK2 (Figure 3D, 3 and 4). As expected,
PRHEE does not bind to the promoter (data not
shown). Quantitative ChIP shows that the differential
regulation of PRH and PRH CC by CK2 occurs across
an extended region of genomic DNA that is known to be
involved in regulation of the Vegfr-1 gene. We infer that
CK2 will have a profound effect on Vegfr-1 gene expres-
sion since phosphorylation of PRH will allow many acti-
vators and epigenetic modulators access to the promoter.
To examine whether the mutated PRH proteins regulate
cell proliferation, K562 cells expressing each protein were
monitored for cell number and apoptotic cell death as
above. Over-expression of PRH brings about
decreased cell number and this is blocked by CK2
over-expression (Figure 4A). In contrast, PRH CC de-
creases cell number but the effects of this protein are
not counteracted by CK2. As expected, PRH EE is
unable to inhibit cell number. CK2 co-expression also
counteracts PRH-induced apoptosis (Figure 4B, 2 and 3)
but it does not counteract the pro-apoptotic effect of
PRH CC (Figure 4B, 4 and 5). These data strongly
support the hypothesis that phosphorylation of PRH by
CK2 abolishes direct transcriptional repression of
VSP genes and that this in turn results in increased cell
survival.
CK2 alters the localization of PRH
We have shown that phosphorylation by CK2 blocks the
DNA-binding activity of PRH (20). We wondered whether
phosphorylation might also inﬂuence the localization of
this protein. PRH, PRH EE and PRH CC are all present
in the nucleus in immunostaining experiments suggesting
that phosphorylation does not affect nuclear localization
(Figure 5B). However, to examine the sub-nuclear local-
ization of these proteins we made use of biochemical
(Figure 5A and C) and in situ sub-cellular fractionation
(Figure 5A). Cells were fractionated into cytoplasmic and
loosely held nuclear proteins [the Post-Nuclear (PN)
fraction] and tightly held nuclear proteins [Nuclear (N)
fraction]. PRH and PRH CC are present in the PN and
N fractions whereas PRHEE is present predominantly in
the PN fraction (Figure 5A). Antibodies against Lamin A/
C and Tubulin were used to verify successful fractionation
and equal loading. The difference in localization was con-
ﬁrmed by in situ fractionation of cells growing on cover-
slips (Figure 5B). While PRH and PRHCC are tightly held
in the nucleus (Figure 5A, rows 4 and 5), PRHEE is readily
depleted from the nucleus following removal of the cyto-
plasmic and loosely held nuclear proteins. Moreover,
over-expression of CK2 results in the loss of co-expressed
Myc-PRH from the nuclear fraction (Figure 5C), further
suggesting that phosphorylation alters PRH localization.
CK2 alters PRH stability
To compare the stability of hypophosphorylated PRH
(hypo-PRH) and pPRH we incubated K562 cells with
the translation inhibitor anisomycin and performed frac-
tionation and western blotting using phosphospeciﬁc PRH
antibodies (20). Endogenous hypo-PRH is present in both
the PN and N compartments (Figure 6A, top, 1 and 5).
pPRH is also present in both fractions, although it is more
prominent in the PN fraction (second top panel, 1 and 5)
conﬁrming the observations made with PRH EE above.
Hypo-PRH is stable over 24 h in both fractions whereas
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AD
B
C
Figure 3. CK2 abolishes DNA binding and the repression of VSP genes by PRH. (A) Vegfr-1 mRNA levels in K562 cells 48 h post-transfection with
an EVC or plasmids expressing PRH, PRH CC and PRH EE either alone, or in conjunction with plasmids expressing CK2 subunits. mRNA levels
were determined as in Figure 1. M+SD, n= 3. *P< 0.05, ns—not signiﬁcant. (B) Western blot of whole-cell extracts from K562 cells transfected as
in (A). (C) K562 cells were transfected as in (A) and chromatin was assessed for distribution of fragment size by electrophoresis on a 1% agarose gel.
M=1kb Marker, chromatin from 2.5 106 cells sonicated for 5min (1) or 10min (2), chromatin from 5 106 cells sonicated for 5min (3) or 10min
(4). Sonication of chromatin from 5 106 cells results in fragments averaging <400 bp and these conditions were used in ChIP. (D) Upper panel—a
cartoon of the Vegfr-1 genomic region, showing relative positions of the Vegfr-1 promoter (bent arrow), clusters of PRH-binding sites (ﬁlled boxes),
and Vegfr-1 primer sequences used for ChIP. Lower panels- enrichment of Myc-PRH proteins bound Vegfr-1 primer sequences relative to input.
Template DNA was precipitated using the Myc 9E10 antibody or IgG. M+SD, n= 4.
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pPRH is unstable (compare lanes 1 and 4 in both panels).
To determine whether endogenous pPRH is a substrate
for the proteasome we incubated cells with anisomycin
and the proteasome inhibitor MG132. In the presence of
both inhibitors pPRH is stabilized in both fractions
(Figure 6B second panel). Incubation of cells with the
proteasome inhibitor Lactacystin also showed the same
result (data not shown). However, there is little change
in the amount of hypo-PRH in either fraction since the
protein is stable over this time period and anisomycin
treatment blocks further protein synthesis (Figure 6B,
top panel). We conclude that pPRH is a substrate for
the proteasome.
Interestingly, the phosphospeciﬁc PRH antibodies
detect an endogenous protein with an apparent molecular
weight of 27 kDa as well as the band corresponding to
endogenous pPRH (Figure 6A and B). A protein that
migrates with a marginally greater apparent molecular
weight is detected using the Myc 9E10 antibody in cells
expressing Myc-tagged PRH (Figure 6C, 2). Furthermore,
the amount of this protein is increased in cells
co-expressing Myc-PRH and CK2 (Figure 6C, 3). These
data suggest that the endogenous 27-kDa protein is a
stable truncated PRH protein produced following the
cleavage of pPRH by the proteasome. Since a protein cor-
responding to this cleavage product is detected by the Myc
antibody when the N-terminally tagged Myc-PRH protein
is expressed in cells, we conclude that the cleavage event
must remove the C-terminal region of the PRH protein.
The apparent size of the truncated protein suggests that
cleavage of pPRH removes the entire C-terminal domain
(amino acids 211–277) leaving the intact N-terminal tran-
scription repression domain and central PRH
homeodomain; we will call this truncated protein
PRHC.
To conﬁrm that phosphorylation of PRH by CK2 is
required for the production of PRHC, we expressed
Myc tagged wild-type PRH, PRH EE phosphomimic and
the PRH CC protein that is unable to be phosphorylated
by CK2 in K562 cells and used western blotting to examine
whether the truncated protein is produced in each case. As
expected based on the experiments described above, when
wild-type is expressed in these cells PRHC is detectable
using the Myc antibody (Figure 6D, 2). Interestingly, the
Myc tagged PRHC protein is present at higher levels in
cells expressing the PRH EE phosphomimic (Figure 6D, 3
and Figure 6E). Furthermore, Myc tagged PRHC is not
detectable in cells expressing PRH CC (Figure 6D, 4).
These data show that phosphorylation at these sites is
required for the production of PRHC. Like the
full-length hypo-PRH protein, the PRHC protein is
stable in the presence of anisomycin (Figure 6A).
However, PRHC is predominantly present in the PN
fraction whereas full-length hypo-PRH is present in both
the PN and N fractions. This is consistent with localization
of PRH EE to the PN fraction (Figure 5B) and further
suggests that PRHC is phosphorylated.
We conclude that in addition to inhibiting the
DNA-binding activity of PRH phosphorylation by
CK2 decreases the nuclear association of this protein
and brings about the cleavage of PRH by the proteasome
resulting in the accumulation of a truncated PRH cleavage
product.
PRH"C is a transdominant negative regulator of PRH
Since the PRHC protein appears to be stable,
accumulating to high levels in the presence of anisomycin
relative to pPRH, we wondered whether this processed
fragment might have an effect on the ability of
hypo-PRH to regulate transcription. To test this we
created a truncated version of PRH EE in which we
deleted the C-terminal domain from amino acids 211 to
277 (PRHC EE). We then examined the effect of this
truncated construct on the ability of PRH to repress tran-
scription of the endogenous Vegfr-1 gene. As expected, a
modest over-expression of PRH results in the repression of
Vegfr-1 mRNA levels (Figure 6F, 2). Also as expected, the
PRHC EE protein fails to repress Vegfr-1 mRNA levels
(Figure 6F, 3). Interestingly, co-transfection of the PRH
A
B
Figure 4. CK2 reverses the inhibition of cell proliferation by PRH but
not PRH CC. (A) K562 cells were transfected as in Figure 3A and 72 h
post-transfection cells were counted as in Figure 1. M+SD, n= 5.
**P< 0.005, ns—not signiﬁcant. (B) K562 cells were co-transfected
with a plasmid expressing GFP and an empty vector (EVC) or
plasmids expressing GFP, PRH proteins and CK2 subunits.
Twenty-four hours post-transfection the cells were dual stained as in
Figure 2. The graph shows the fold change in the number of apoptotic
cells (AV+/PI+) after gating for GFP+cells. M+SD, n= 3. *P< 0.05,
ns—not signiﬁcant.
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expression vector with increasing amounts of the PRHC
EE expression vector results in a dose-dependent reduction
in the repression of Vegfr-1 mRNA levels by PRH (Figure
6F, 4–6). Expression of PRHC EE does not change the
expression level of PRH in this experiment (Figure 6G).
These data show that PRHC EE acts a transdominant
negative regulator of the full-length PRH protein. This
suggests that the endogenous PRHC protein produced
by the proteosomal digestion of pPRH will also act as a
transdominant negative regulator of PRH activity.
PRH"C sequesters TLE co-repressor proteins
We have shown previously that PRH recruits members of
the TLE family of co-repressor proteins in order to repress
the transcription of its target genes (18). An Eh1 motif
present in the N-terminal repression domain of PRH
mediates binding to TLE proteins and an F32E
mutation in this motif blocks both binding to TLE
proteins and transcriptional co-repression (18,22). The
PRHC EE protein carries the Eh1 motif and although
this protein is unable to repress transcription we wondered
whether it might bind and sequester TLE proteins
and thereby act as transdominant negative for full-length
PRH. To test this hypothesis we ﬁrst expressed
PRHCEE in K562 cells and performed co-immu-
noprecipitation assays for TLE. The PRHCEE protein
is able to co-immunoprecipitate FLAG tagged TLE
(Figure 7A) whereas this protein is not
A
C
B
Figure 5. A PRH phosphomimic shows altered intracellular localization. (A) K562 cells were transfected with vectors expressing Myc-tagged PRH,
PRH CC or PRH EE and then fractionated into cytoplasmic and loosely held nuclear proteins (PN) and tightly held nuclear proteins (N). The
extracts were western blotted for PRH using the Myc antibody (top panel). The blot was stripped and reprobed for Tubulin and Lamin A/C as
controls for fractionation and loading. (B) K562 cells were transiently transfected as above and then adhered to polylysine coated coverslips. Top
three rows, whole-cell images. Bottom three rows, cells treated with CSK buffer containing 0.1% SDS to remove cytoplasmic and loosely held
nuclear proteins. DNA was stained with DAPI. Tubulin was visualized using an anti-Tubulin antibody and FITC-labelled secondary. PRH was
visualized using the Myc 9E10 antibody and a TRITC-labelled secondary. Viewed using a Leica DM IRBE confocal microscope. (C)K562 cells were
transfected with plasmids expressing Myc-PRH alone or Myc-PRH and HA-CK2 a and b subunits (as in Figure 1A). The cells were then
fractionated into whole-cell extract (WC), PN and N fractions as in (part A above). The extracts were western blotted for PRH using the Myc
antibody (top panel). Tubulin and Lamin A/C were used as controls for fractionation and loading.
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co-immunoprecipitated by control antibodies.
Furthermore, although PRHCEE and full-length PRH
are expressed at equivalent levels, PRHCEE is able to
co-immunoprecipitate FLAG-TLE much more ro-
bustly than full-length PRH (Figure 7A, compare lanes
2 and 5 top panel). This suggests that PRHCEE binds
to TLE with higher afﬁnity than PRH. To conﬁrm
the PRHCEE-TLE interaction and to show that en-
dogenous PRHC binds to TLE, we performed a co-
immunoprecipitation assay using FLAG-TLE as
bait. Endogenous PRHC co-immunoprecipitates with
FLAG-TLE but does not co-immunoprecipitate with
control antibodies (Figure 7B).
To determine whether binding to TLE is important for
the ability of PRHC to act as a transdominant negative
protein we introduced the well-characterized F32E
mutation into PRHC EE. The PRHC EE F32E
mutant fails to act as a dominant negative for full-length
PRH (Figure 7C) although the protein is expressed
at equivalent levels to PRHC EE (Figure 7D).
A
E F G
B C
D
Figure 6. pPRH is rapidly cleaved by the proteasome to produce a stable product. (A) Untransfected K562 cells were treated with Anisomycin for
the times indicated and then fractionated as in Figure 5. The extracts were western blotted for endogenous PRH using antibodies that recognize
hypo-PRH or pPRH. The blot was stripped and reprobed for Lamin A/C and Tubulin as controls for fractionation and loading. (B) The experiment
described in (A) was repeated using K562 cells treated with 40 mM anisomycin and the proteasome inhibitor MG132 (10 mM). (C) K562 cells were
transiently transfected with plasmids expressing Myc-PRH (5mg) or Myc-PRH (5mg) and HA-CK2 subunits (3 mg each). Twenty-four hours
post-transfection whole-cell extracts were western blotted for Myc-tagged proteins using the Myc9E10 antibody. The blot was stripped and
reprobed for Tubulin as a control for loading. (D) K562 cells were transiently transfected with EVC or plasmids expressing Myc-PRH (5 mg),
Myc-PRH EE (5mg) and Myc-PRH CC (5 mg). Twenty-four hours post-transfection whole-cell extracts were western blotted for Myc-tagged proteins
and Tubulin as a control for loading. (E) The ratio of PRHC to full-length PRH was determine from three independent experiments performed as
in (D). *P< 0.05, (F) Vegfr-1 mRNA levels in K562 cells 48 h post-transfection with plasmids expressing Myc-PRH (5 mg) alone, Myc-PRHC EE
(5 mg) alone or Myc-PRH (5 mg) and Myc-PRHC EE (1, 3 and 5mg). mRNA levels were determined by qPCR and compared to Gapdh. Mean and
standard deviation (M+SD), n= 5. *P< 0.05, **P< 0.01, ns—not signiﬁcant. (G) Myc-PRH and Myc-PRHC EE protein levels in the experiment
described in (F) were determined by western blotting. Lamin A/C was used as a control for loading.
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We conclude that PRHC sequesters TLE co-repressor
proteins and that this is responsible for the ability of
this protein to act a transdominant negative regulator of
full-length PRH.
DISCUSSION
PRH is an oligomeric transcription factor that regulates
the proliferation of multiple cell types in development. We
have demonstrated previously that PRH also controls the
proliferation of haematopoietic and breast tumour cells
(10). One mechanism by which PRH can control cell pro-
liferation is by regulating the transcription of multiple
genes encoding components of the VSP. Here we have
shown using quantitative ChIP that PRH can be
immunoprecipitated at regions extending from 5600 bp 50
to 1700 bp 30 of the Vegfr-1 ﬁrst exon and is most strongly
associated with sequences 1-kb upstream of the core
Vegfr-1 promoter. Since PRH distorts and compacts
long stretches of DNA in vitro (16,17) and binds to
extended tandem arrays of repeated 50-ATTAA-30 se-
quences and related DNA sequences, we speculate that
the presence of PRH across the Vegfr-1 promoter
reﬂects the DNA-binding properties of the PRH
oligomer. Presumably, the binding of PRH across exten-
sive promoter sequences contributes to the repression of
transcription by excluding multiple activator proteins.
Here we have demonstrated that CK2 is able to antagon-
ize PRH binding across the entire Vegfr-1 promoter
alleviating PRH-mediated repression. It would seem
likely that PRH represses other VSP genes in a similar
manner and that CK2 abrogates PRH-mediated repres-
sion in each case. In keeping with this conclusion we
have shown here that CK2 abrogates the repression of
Vegf mRNA levels by PRH. Since PRH represses
multiple VSP genes it is likely that phosphorylation of
PRH by CK2 results in an increase in VEGF signalling.
We have shown previously that in K562 cells PRH KD
results in increased VEGF signalling and increased cell
survival (10). In cells that express PRH, the interplay
between PRH and CK2 and the consequent regulation
of cell survival is likely to be important in allowing the
appropriate level of cell proliferation in response to cues
from the extracellular and intracellular environment.
In addition to blocking the DNA-binding activity of
PRH, phosphorylation by CK2 decreases PRH nuclear
association and targets this protein for cleavage by the
proteasome. It would seem likely that all of these
A
B D
C
Figure 7. The transdominant negative activity of PRHC requires binding to TLE co-repressor proteins. (A) K562 cells were co-transfected with
expression vectors for FLAG-TLE1 and Myc-PRH or FLAG-TLE1 and Myc-PRHC EE and nuclear extracts prepared for
co-immunoprecipitation. The top panel shows a western blot for FLAG-TLE1 in the nuclear extract (1 and 4) and in the same extract after
immunoprecipitation with the Myc9E10 antibody (2 and 5) or control rabbit IgG antibody (3 and 6). The blot was striped and reprobed with
the Myc9E10 antibody to conﬁrm expression of Myc-PRH and Myc-PRHC EE (bottom panel). The secondary antibody also picks up the mouse
IgG light chain (IgG LC). (B) K562 cells were transfected with an expression vector for FLAG tagged TLE1 and nuclear extracts prepared for
co-immunoprecipitation. The bottom panel shows a western blot for endogenous pPRH in the nuclear extract (1) and after immunoprecipitation with
the FLAG antibody (2) or control mouse IgG antibody (3). (C) Vegfr-1 mRNA levels in K562 cells 48 h post-transfection with plasmids expressing
Myc-PRH (5mg) alone, Myc-PRH (5mg) and Myc-PRHC EE (5mg) or and Myc-PRH and Myc-PRHC EE F32E (5 mg). mRNA levels were
determined by qPCR and compared to Gapdh. Mean and standard deviation (M+SD), n= 3. *P< 0.05, (D) Cell extracts from (C) were used to
determine the expression levels of Myc-PRHC EE and Myc-PRHC EE F32E using western blotting. The blot was stripped and reprobed for
Lamin A/C as a loading control.
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mechanisms contribute to the ability of CK2 to antagonize
the inhibition of cell proliferation by PRH. This suggests a
model in which phosphorylation of PRH by CK2 leads to
loss of DNA binding, loss of nuclear retention, increased
PRH degradation and the production of a phosphorylated
and truncated PRH protein which we have termed
PRHC (HhexC). The PRHC protein then acts as a
transdominant negative regulator of full-length PRH very
likely via the sequestration of TLE co-repressor proteins.
The production of the PRHC following the cleavage of
pPRH would thus provide a very effective mechanism to
switch off PRH in cells. The PRHC protein appears to
be very stable in contrast to the rapidly degraded pPRH
protein. The sustained phosphorylation of even a small
percentage of PRH by CK2 would result in the accumu-
lation of large amounts of PRHC that could down-
regulate the activity of unphosphorylated PRH. This
novel regulatory mechanism implies that small changes
in CK2 activity and the overall level of PRH phosphoryl-
ation could have dramatic effects on the ability of PRH to
regulate transcription. TLE proteins are recruited by
many other transcription factors to facilitate the regula-
tion of diverse genes and it is likely that PRHC will also
regulate some or all of these targets.
Finally it is important to point out that these experi-
ments suggest a molecular rationale for the use of CK2
inhibitors in the treatment of primary CML. The restor-
ation of PRH activity through inhibition of CK2 may be
particularly of value in Imatinib or Dasatinib resistant
CML or in targeting the quiescent cancer stem cells in
CML which are less dependent on BCR-ABL activity
(24). These data also support a role for PRH as a
tumour suppressor gene in haematopoietic myeloid
lineages.
SUPPLEMENTARY DATA
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